key: cord-0938294-drplu6bp
authors: Lui, David Tak Wai; Lee, Chi Ho; Chow, Wing Sun; Lee, Alan Chun Hong; Tam, Anthony Raymond; Fong, Carol Ho Yi; Law, Chun Yiu; Leung, Eunice Ka Hong; To, Kelvin Kai Wang; Tan, Kathryn Choon Beng; Woo, Yu Cho; Lam, Ching Wan; Hung, Ivan Fan Ngai; Lam, Karen Siu Ling
title: Role of non‐thyroidal illness syndrome in predicting adverse outcomes in COVID‐19 patients predominantly of mild‐to‐moderate severity
date: 2021-04-12
journal: Clin Endocrinol (Oxf)
DOI: 10.1111/cen.14476
sha: 3a6f5731c5e75246740062e4780ecf93c8d5bc37
doc_id: 938294
cord_uid: drplu6bp

OBJECTIVE: Existing studies reported the potential prognostic role of non‐thyroidal illness syndrome (NTIS), characterized by low triiodothyronine (T3) with normal/low thyroid‐stimulating hormone (TSH), mainly in severe COVID‐19. None considered the significant impact of SARS‐CoV‐2 viral load on adverse outcomes. We aimed to clarify the prognostic role of NTIS among predominantly mild‐to‐moderate COVID‐19 patients. DESIGN: A prospective study of COVID‐19 patients. PATIENTS AND MEASUREMENTS: Consecutive adults admitted to Queen Mary Hospital for confirmed COVID‐19 from July to December 2020 were prospectively recruited. SARS‐CoV‐2 viral load was represented by cycle threshold (Ct) values from real‐time reverse transcription‐polymerase chain reaction of the respiratory specimen on admission. Serum TSH, free thyroxine and free T3 were measured on admission. The outcome was deterioration in clinical severity, defined as worsening in ≥1 category of clinical severity according to the Chinese National Health Commission guideline. RESULTS: We recruited 367 patients. At baseline, 75.2% had mild disease, and 27 patients (7.4%) had NTIS. Fifty‐three patients (14.4%) had clinical deterioration. Patients with NTIS were older, had more comorbidities, worse symptomatology, higher SARS‐CoV‐2 viral loads and worse profiles of inflammatory and tissue injury markers. They were more likely to have clinical deterioration (p < .001). In multivariable stepwise logistic regression analysis, NTIS independently predicted clinical deterioration (adjusted odds ratio 3.19, p = .017), in addition to Ct value <25 (p < .001), elevated C‐reactive protein (p = .004), age >50 years (p = .011) and elevated creatine kinase (p = .017). CONCLUSIONS: Non‐thyroidal illness syndrome was not uncommon even in mild‐to‐moderate COVID‐19 patients. NTIS on admission could predict clinical deterioration in COVID‐19, independent of SARS‐CoV‐2 viral load, age and markers of inflammation and tissue injury.

The occurrence of non-thyroidal illness syndrome (NTIS), characterized by low triiodothyronine (T3) along with normal or low thyroidstimulating hormone (TSH), 1 was reported in several cohorts of patients with coronavirus disease 2019 (COVID- 19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2 Although it was well demonstrated that NTIS occurred more frequently among patients with more severe COVID-19, 3 whether the occurrence of NTIS on admission predicts adverse clinical outcomes in patients is more clinically relevant.

Since October 2020, several studies evaluating the predictive value of NTIS in the clinical course of COVID-19 have been published. Preliminary findings from a retrospective analysis of a small Chinese cohort revealed that 25 patients with thyroid dysfunction (predominantly, but not exclusively, NTIS) had worse biochemical and inflammatory profiles, and a higher risk of mortality than those without thyroid dysfunction. 4 Further studies have shown that lower free T3 (fT3) levels, but not free thyroxine (fT4) or TSH, were associated with COVID-19-related adverse events such as severe disease, ventilatory requirement and mortality, 5,6 echoed by another study revealing that NTIS predicted disease severity. 7 However, all these studies focused on COVID-19 patients with more severe disease, whereas most COVID-19 patients belonged to the mild disease spectrum. 8 Notably, none of these studies considered the significant impact of SARS-CoV-2 viral load on admission on COVID-19-related adverse outcomes. 9 We have previously reported thyroid dysfunction in 191 patients with COVID-19, which included mainly patients with low TSH suggestive of subclinical thyrotoxicosis due to thyroiditis, and those with low fT3 compatible with NTIS. 10 Patients with low fT3 were more likely to have clinical deterioration than those with normal fT3.

In contrast, the likelihood of clinical deterioration was comparable between patients with low TSH and those with normal TSH. While these findings suggested that among the categories of thyroid dysfunction in COVID-19, NTIS appeared to hold a unique prognostic role in COVID-19, further evaluation of the independent prognostic role of NTIS was limited by the sample size. 10 Hence, we carried out the current prospective study, an extension to our previous study 10 with a longer recruitment period and a significantly larger sample size, to examine the frequency of NTIS, and clarify the prognostic significance of NTIS in COVID-19 patients predominantly of mild-to-moderate severity, taking into consideration a range of COVID-19-related prognostic markers.

Public health ordinance in Hong Kong required all patients tested positive for COVID-19 be admitted to hospital, 11 including those detected on contact tracing and Universal Community Testing Programme, 12 regardless of symptoms. Our institution, Queen Mary Hospital, is one of the major centres in Hong Kong receiving confirmed COVID-19 patients. Consecutive adult patients (aged ≥18 years) admitted to Queen Mary Hospital for COVID-19 between 21 July 2020 and 21 December 2020 were prospectively recruited. 10 The presence of SARS-CoV-2 was confirmed in all patients by RT-PCR from the nasopharyngeal swab (NPS) and/or deep throat saliva (DTS), using the LightMix SarbecoV E-gene assay (TIB Molbiol, Berlin, Germany) which targeted the envelope protein (E) gene of SARS-CoV-2 as we described previously. 13 Germany), using porcine TSHR. Anti-TSHR >1 IU/L was considered positive. Patients with abnormal thyroid function tests (TFTs; defined by any abnormalities in TSH, fT4 or fT3) could therefore be classified into three groups. The first included patients with NTIS as defined by low fT3 with normal/low TSH. 1 The second were those with likely pre-existing autoimmune thyroid disorders as defined by A few sensitivity analyses were performed. Firstly, we repeated the multivariable stepwise logistic regression analysis by including not only the variables with statistical significance in the univariate analysis, but also those with biological plausibility which included obesity, age, cardiovascular diseases, pulmonary diseases, diabetes, hypertension, smoking and male. 19 Secondly, we repeated the multivariable stepwise logistic regression analysis by using Charlson comorbidity index, a composite score of comorbidities, instead of individual comorbidities. Thirdly, we repeated the multivariable stepwise logistic regression analysis by using thyroid hormones (fT4 and fT3) as continuous variables instead of NTIS as a categorical variable. Notably, comparing with patients with normal TFTs, those with NTIS had a higher likelihood of clinical deterioration (p < .001), mainly driven by the higher likelihood of oxygen requirement (p < .001) and intensive care unit admission (p = .005). In contrast, there was no significant difference in clinical outcomes between patients with normal TFTs and those with pre-existing autoimmune thyroid disorders or with abnormal TFTs compatible with thyroiditis. (Table 1) .

We further characterized patients with NTIS and studied the prognostic implication of NTIS, with reference to patients with normal TFTs. Table 2 We then included all the 14 variables showing univariate significance in Table 3 into the multivariable stepwise logistic regression analysis to identify the independent predictors of clinical deterioration. In the multivariable stepwise logistic regression analysis ( 

Firstly, we repeated the multivariable stepwise logistic regression analysis by further including variables with biological plausibility selected a priori, that is, obesity, age, cardiovascular diseases, pulmo- 

Reassessment TFTs were arranged at around 3 months after discharge to assess for resolution or progression. Forty-three of the 62 patients with initial abnormal TFTs had reassessment TFTs. Among the 27 patients categorized as NTIS, 20 had reassessment TFTs.

Eighteen recovered, but two still had abnormal TFTs. One patient had NTIS upon reassessment when he was admitted for fluid overload and clinically ill. The other patient developed T3-toxicosis at 3 months, followed by spontaneous resolution another 3 months to be an independent predictor of clinical deterioration, in addition to age and markers of inflammation and tissue injury.

The frequency of NTIS in our cohort of mild-to-moderate COVID-19 was 7.4%, in line with the previous report of 5.9% among 34 non-severe COVID-19 patients in a Chinese cohort. 5 Not surprisingly, the frequency of NTIS was lower than that among patients with more severe baseline clinical severity, which has been reported to occur in up to 20%-30% among severe COVID-19 patients. 4, 7 The baseline clinical profile of patients with NTIS, in comparison with patients with normal TFTs, was similar to those reported in cohorts of more severe COVID-19 patients, 6, 7 in that patients with NTIS were older, more symptomatic with fever and shortness of breath, and had more lymphopenia, higher markers of inflammation and tissue injury.

Identifying independent risk factors of COVID-19-related adverse outcomes helps clinicians triage at-risk patients for more intensive monitoring and aggressive therapy. Some of the more consistently reported risk factors were older age, 20-23 higher levels of inflammatory markers including CRP, 24 higher levels of tissue injury markers 21, 23 including CK 25 and worse symptoms. 23 Recently, SARS-CoV-2 viral load has also been shown to have an important prognostic implication in COVID- 19, 9, 26 which is an important factor to consider when studying outcomes of a viral illness. We showed that NTIS remained to be an independent pre- The association between NTIS and COVID-19-related adverse outcomes could be explained by the cytokine storm, which may suppress central TSH and 5'-deiodinases activity, and in turn be associated with worse clinical outcomes. 7 

Non-thyroidal illness syndrome was not uncommon, occurring in over 7%, even in COVID-19 patients with predominantly mild-tomoderate disease severity on admission. The occurrence of NTIS on admission could predict clinical deterioration in COVID-19, independent of SARS-CoV-2 viral load, age and markers of inflammation and tissue injury.

None.

The author has no conflict of interest to declare. KSLL initiated and supervised the study, is the guarantor of this work and as such had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Values reaching statistical significance are in bold.

Abbreviation: CI, confidence interval.

Datasets generated during and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Karen Siu Ling Lam https://orcid.org/0000-0001-5757-541X

Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection

Potential interaction between SARS-CoV-2 and thyroid: a review

Thyroid function analysis in 50 patients with COVID-19: a retrospective study

Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19

Thyroid hormone concentrations in severely or critically ill patients with COVID-19

Sick euthyroid syndrome on presentation of patients with COVID-19: a potential marker for disease severity

Euthyroid sick syndrome in patients with COVID-19

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention

Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease

Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Online appointments for Universal Community Testing Programme to begin tomorrow

Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore wholegenome sequencing

clinical practice guideline for the evaluation and management of chronic kidney disease chapter 1: definition and classification of CKD

Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients

To interpret the SARS-CoV-2 test, consider the cycle threshold value

Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment

Obesity: a critical risk factor in the COVID-19 pandemic

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Identification of risk factors for in-hospital death of COVID-19 pneumonia -lessions from the early outbreak

Risk factors prediction, clinical outcomes, and mortality in COVID-19 patients

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China

C-reactive protein and clinical outcomes in patients with COVID-19

Rhabdomyolysis is associated with in-hospital mortality in patients with COVID-19

SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19

T3 preserves respiratory function in sepsis

Pulmonary biophysical effects of triiodothyronine augmentation during sepsis-induced hypothyroidism

Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial

Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild-tomoderate severity